Menopause typically occurs in women around age 50. Accompanying this life event is a decline in estrogen levels and an increase in the rate of decline in women’s bone density. This rapid bone loss increases women’s subsequent risk of developing osteoporosis, a disease characterized by low bone density and increased bone fragility. Among the most serious consequences of osteoporosis is fracture of the hip, which may result in substantial morbidity, prolonged hospitalization, and death. Estrogen can prevent bone loss after menopause by replacing the body’s own estrogen. Given the serious consequences of osteoporosis, some osteoporosis experts have recommended that women have their bone mineral density measured at the time of menopause and those with the lowest bone mineral density be offered hormone replacement therapy, comprising estrogen given alone or in combination with the hormone progestin.

This background paper, *Effectiveness and Costs of Osteoporosis Screening and Hormone Replacement Therapy*, assesses the medical benefits and costs of both screening and hormone replacement therapy. It is divided into two volumes. The first volume, *Cost-Effectiveness Analysis*, presents the results of a model that estimates the cost per year of life gained from osteoporosis screening and hormone replacement therapy in postmenopausal women. The second volume, *Evidence on Benefits, Risks, and Costs*, provides the basis for the assumptions about the costs and effects of screening and hormonal replacement therapy used in the cost-effectiveness model.

This background paper is one of three documents resulting from OTA’s assessment of policy issues in the prevention and treatment of osteoporosis. This assessment was requested by the Senate Special Committee on Aging, Senator Charles Grassley and Senator John Glenn, and the House Select Committee on Aging, Representative Olympia J. Snowe, Representative Benjamin A. Gilman, and former Representatives Brian J. Donnelly, Thomas J. Downey, and Patricia F. Saiki. Two background papers in this series have been issued, both in July 1994: *Public Information about Osteoporosis: What’s’ Available, What’s Needed?, and Hip Fracture Outcomes in People Age Fifty and Over.*
Advisory Panel

Robert P. Heaney  
John A. Creighton Professor  
Creighton University  
Omaha, Nebraska

Steven R. Cummings  
Research Director  
College of Medicine  
University of California  
San Francisco, California

Barbara L. Drinkwater  
Research Physiologist  
Pacific Medical Center  
Seattle, Washington

Deborah T. Gold  
Assistant Professor  
Duke University Medical Center  
Durham, North Carolina

Susan L. Greenspan  
Director  
Osteoporosis Prevention and Treatment Center  
Beth Israel Hospital  
Boston, Massachusetts

Caren Marie Gundberg  
Assistant Professor  
Department of Orthopedics  
Yale University School of Medicine  
New Haven, Connecticut

Sylvia Hougland  
Dallas, Texas

Conrad C. Johnston  
Director  
Division of Endocrinology & Metabolism  
Indiana University School of Medicine  
Indianapolis, Indiana

Shiriki K. Kumanyika  
Associate Director for Epidemiology  
Center for Biostatistics & Epidemiology  
College of Medicine  
Pennsylvania State University  
Hershey, Pennsylvania

Edward O. Lanphier, II  
Executive Vice President for Commercial Development  
Somatix Therapy Corporation  
Alameda, California

Donald R. Lee  
Vice President  
Procter and Gamble Pharmaceuticals  
Norwich, New York

Robert Lindsay  
Chief, Internal Medicine  
Helen Hayes Hospital  
West Haverstraw, New York

Betsy Love  
Program Manager  
Center for Metabolic Bone Disorders  
Providence Medical Center  
Portland, Oregon

Robert Marcus  
Director  
Aging Study Unit  
Virginia Medical Center  
Palo Alto, California

Lee Joseph Melton, III  
Head, Section of Clinical Epidemiology  
Department of Health Sciences Research  
Mayo Clinic  
Rochester, Minnesota

Gregory D. Miller  
Vice President  
Nutrition Research/Technical Services  
National Dairy Council  
Rosemont, Illinois
Morris Notelovitz  
President and Medical Director  
Women’s Medical & Diagnostic Center & the Climacteric Clinic, Inc.  
Gainesville, Florida

William Arno Peck  
Dean  
Washington University School of Medicine  
St. Louis, Missouri

Diana B. Petitti  
Director, Research and Evaluation  
Kaiser Permanente Southern California Permanente Medical Group  
Pasadena, California

Neil M. Resnick  
Chief, Geriatrics  
Brigham and Women’s Hospital  
Boston, Massachusetts

Gideon A. Rodan  
Executive Director  
Department of Bone Biology  
Merck, Sharp & Dohme Research West Point, Pennsylvania

Mehrsheed Sinaki  
Professor, Physical Medicine and Rehabilitation  
Mayo Medical School  
Rochester, Minnesota

Milton C. Weinstein  
Henry J. Kaiser Professor  
Health Policy and Management  
Harvard School of Public Health  
Boston, Massachusetts
Project Staff

Clyde J. Behney
Assistant Director, OTA

Sean R. Tunis
Health Program Director

ADMINISTRATIVE STAFF
Louise Staley
Office Administrator

Carolyn Martin
Administrative Secretary

Monica Finch
Word Processing Specialist

PRINCIPAL CONTRACTORS
Dennis M. Black
Department of Clinical Epidemiology
University of California, San Francisco

Elliott Pickar
Consultant, Rockville, MD

PROJECT STAFF
Robert McDonough
Study Director

Judith L. Wagner
Senior Associate

Katie Maslow
Senior Associate

Douglas Teich
Senior Analyst

Laura Stricker
Research Assistant

William Adams
Research Assistant

Julia Bidwell
Research Assistant

Angela Schreiber
Research Assistant